231 related articles for article (PubMed ID: 20171408)
1. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.
Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Tanaka M; Kamoi D; Kawamura Y; Yamada S; Hayashi M; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
Clin Ther; 2010 Jan; 32(1):24-33. PubMed ID: 20171408
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Yamada S; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1034-40. PubMed ID: 18322041
[TBL] [Abstract][Full Text] [Related]
3. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis.
Kawamura Y; Ishii H; Aoyama T; Tanaka M; Takahashi H; Kumada Y; Toriyama T; Murohara T
J Vasc Surg; 2009 Nov; 50(5):1057-62. PubMed ID: 19782527
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Iida O; Yokoi H; Soga Y; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Shintani Y; Miyamoto A; Hirano K; Miyashita Y; Tsuchiya T; Shinozaki N; Nakamura M; Isshiki T; Hamasaki T; Nanto S;
Circulation; 2013 Jun; 127(23):2307-15. PubMed ID: 23652861
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
6. Impact of Scoring Balloons on Percutaneous Transluminal Angioplasty Outcomes in Femoropopliteal Lesions.
Horie K; Tanaka A; Taguri M; Inoue N
J Endovasc Ther; 2020 Jun; 27(3):481-491. PubMed ID: 32249658
[No Abstract] [Full Text] [Related]
7. Comparison of Atherectomy to Balloon Angioplasty and Stenting for Isolated Femoropopliteal Revascularization.
Bai H; Fereydooni A; Zhuo H; Zhang Y; Tonnessen BH; Guzman RJ; Ochoa Chaar CI
Ann Vasc Surg; 2020 Nov; 69():261-273. PubMed ID: 32512112
[TBL] [Abstract][Full Text] [Related]
8. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series.
Conrad MF; Cambria RP; Stone DH; Brewster DC; Kwolek CJ; Watkins MT; Chung TK; LaMuraglia GM
J Vasc Surg; 2006 Oct; 44(4):762-9. PubMed ID: 17012001
[TBL] [Abstract][Full Text] [Related]
9. Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study.
Soga Y; Hamasaki T; Edahiro R; Iida O; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Aodo K;
J Endovasc Ther; 2018 Jun; 25(3):306-312. PubMed ID: 29706129
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis).
Dippel EJ; Makam P; Kovach R; George JC; Patlola R; Metzger DC; Mena-Hurtado C; Beasley R; Soukas P; Colon-Hernandez PJ; Stark MA; Walker C;
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):92-101. PubMed ID: 25499305
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes and predictors of iliac angioplasty with selective stenting.
Kudo T; Chandra FA; Ahn SS
J Vasc Surg; 2005 Sep; 42(3):466-75. PubMed ID: 16171589
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease.
Kumada Y; Aoyama T; Ishii H; Tanaka M; Kawamura Y; Takahashi H; Toriyama T; Aoyama T; Yuzawa Y; Maruyama S; Matsuo S; Murohara T
Nephrol Dial Transplant; 2008 Dec; 23(12):3996-4001. PubMed ID: 18596131
[TBL] [Abstract][Full Text] [Related]
13. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.
Iida O; Nanto S; Uematsu M; Morozumi T; Kotani J; Awata M; Onishi T; Ito N; Oshima F; Minamiguchi H; Kitakaze M; Nagata S
Circ J; 2005 Oct; 69(10):1256-9. PubMed ID: 16195627
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K
J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
[TBL] [Abstract][Full Text] [Related]
16. Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease.
Conrad MF; Kang J; Cambria RP; Brewster DC; Watkins MT; Kwolek CJ; LaMuraglia GM
J Vasc Surg; 2009 Oct; 50(4):799-805.e4. PubMed ID: 19786239
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous revascularization of femoropopliteal artery disease: PTA and PTA plus stent. Results after six years' follow-up.
Pozzi Mucelli F; Fisicaro M; Calderan L; Malacrea M; Mazzone C; Cattin L; Scardi S; Pozzi Mucelli R
Radiol Med; 2003 Apr; 105(4):339-49. PubMed ID: 12835627
[TBL] [Abstract][Full Text] [Related]
18. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
20. Drug-Coated Balloon vs. Conventional Balloon Angioplasty in Dialysis Patients With Symptomatic Femoropopliteal Disease - A Matched Comparison.
Chou HH; Huang HL; Hsieh CA; Jang SJ; Tzeng IS; Ko YL
Circ J; 2018 Jun; 82(7):1908-1916. PubMed ID: 29695655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
